Development of care techniques to reduce (alleviate) symptoms of pain and numbness as an aftereffect of stroke

Development of care technology for pain and numbness as aftereffects of stroke - Development of care technology for pain and numbness as aftereffects of stroke

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052975

Enrollment

Registered

2023-12-01

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Hand massage for 15 minutes at intervals of once a week for 2 months (8 times in total)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with pain and numbness as a sequela of stroke 2.Pain and numbness intensity of 5/10 or higher on the Visual Analogue Scale (VAS) 3.Patients who can continuously participate in the care intervention for about 30 minutes once a week for 1-2 months. 4.Patients who are able to maintain a sitting position for about 30 minutes.

Exclusion criteria

Exclusion criteria: 1.Patients who are judged by the attending physician, charge nurse, or principal investigator to be unsuitable as research participants at the time consent is obtained. 2.Patients who are judged by the attending physician, charge nurse, or principal investigator to be "unable to give effective informed consent due to language impairment, cognitive impairment, etc.". 3.Other patients who are judged by the principal investigator to be inappropriate as research participants.

Design outcomes

Primary

Measure	Time frame
1. Pain level: VAS (Visual Analogue Scale) [before and after the intervention, and upon waking and sleeping], SF-MPQ-2 (Short-Form McGill Pain Questionnaire-2) [before intervention, 1 month after, 2 months after]. 2. Presence and amount of analgesic medication [daily]. Impact on life: SF-12 (MOS 12-Item Short-Form Health Survey) [before, one month after, and two months after the intervention], HADS (Hospital Anxiety and Depression Scale) [before, one month after, and two months after the intervention], SIAS (Stroke Impairment Assessment Set) [before intervention]. 4. Relaxation effect: Heart rate variability [each time during intervention].	—

Measure

Time frame

1. Pain level: VAS (Visual Analogue Scale) [before and after the intervention, and upon waking and sleeping], SF-MPQ-2 (Short-Form McGill Pain Questionnaire-2) [before intervention, 1 month after, 2 months after]. 2. Presence and amount of analgesic medication [daily]. Impact on life: SF-12 (MOS 12-Item Short-Form Health Survey) [before, one month after, and two months after the intervention], HADS (Hospital Anxiety and Depression Scale) [before, one month after, and two months after the intervention], SIAS (Stroke Impairment Assessment Set) [before intervention]. 4. Relaxation effect: Heart rate variability [each time during intervention].

—

Countries

Japan

Contacts

Public ContactKAZUE TOKI

Senri Kinran University Faculty of Nursing

k-toki@cs.kinran.ac.jp0668727129

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026